FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Garner Elizabeth						2. Issuer Name and Ticker or Trading Symbol AGILE THERAPEUTICS INC [AGRX]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
Carner Enzavetti											-	_		Directo	or		10% Ov	vner	
(Last) (First) (Middle)				Date of Earliest Transaction (Month/Day/Year)								_	X Officer below)	(give title		Other (s below)	specify		
					02/19/2015									Sr. VP & Chief Medical Officer					
101 POOR FARM ROAD																			
(Street)					4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line)					
PRINCETON NJ 08540														X Form filed by One Reporting Person					
(City) (State) (Zip)														Form filed by More than One Reporting Person					
(City)	(5	iale)	(ZIÞ)																
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of	ction 2A. Deemed				3. 4. Securit			ties Acquired (A) o		5. Amou	es Form		nership	7. Nature					
Date (Month/Date					Execution Date, ay/Year) if any					Disposed Of (D) (Instr. 3, 4			d Securitie Beneficia		of Indirect Beneficial				
(MOIIII				nontin Da	y/ I cai		(Month/Day/Yea				"			Owned F	Following (I) ((Instr. 4)	Ownership	
								0.4	.,		unt (A) or D			Reported Transaction(s)			(Instr. 4)		
									Code	٧	Amount	(D)	Price	(Instr. 3	and 4)				
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
(e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Dat if any (Month/Day/Ye	C₀	ınsacti de (Ins			6. Date Exercisa Expiration Date (Month/Day/Year			of Securiti Underlying Derivative	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	ly	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)		
				Co	de V		(A)	(D)	Date Exercisable		xpiration ate	Title	Amount or Number of Shares						
Employee Stock Option (Right to Buy)	\$9.45	02/19/2015		A			50,000		(1)	0:	2/18/2025	Common Stock	50,000	\$0	50,000)	D		
Employee Stock Option (Right to Buy)	\$10.75	02/19/2015		A			50,000		(1)	0:	2/18/2025	Common Stock	50,000	\$0	50,000)	D		

Explanation of Responses:

1. This option was granted on February 19, 2015. 25% of the shares subject to the stock option vest on February 19, 2016, and the remaining shares vest in 36 substantially equal monthly installments over the following three years such that the option will be fully vested on February 19, 2019.

> /s/ Scott M. Coiante, Attorney-02/23/2015 in-Fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.